HSV529, a vaccine for herpes simplex virus 2 (HSV2), showed favorable results in a recent phase 1 trial. The study found that the vaccine was safe and elicited antibody and T-cell responses in HSV seronegative adults. According to details published in the Journal of Infectious Diseases, the randomized, double-blind, placebo-controlled trial. BIRMINGHAM, Ala. (WBRC) - UAB and Children’s of Alabama researchers believe they may have found a new way to help treat pediatric tumors. A modified herpes virus, alone and in combination with radiation, has been shown to be well tolerated with early signs of clinical effectiveness in pediatric patients with high-grade brain tumors, or.